VANCOUVER, BC / ACCESSWIRE / May 30, 2017 / LED Medical Diagnostics Inc. (TSX-V: LMD; OTCQB: LEDIF; FRA: LME) (“LED Medical” or the “Company”) today announced its financial results for the first quarter ended March 31, 2017, reported in United States dollars and in accordance with International Financial Reporting Standards (“IFRS”). The Company’s results are presented in comparison to the first quarter ended March 31, 2016. All balances are expressed in United States dollars unless otherwise stated.

“A noteworthy accomplishment this quarter was the acquisition of Apteryx Inc., a profitable, Ohio based imaging software company, on February 10th. This transformative event is both additive and accretive to the Company and provides several unique synergies to our core business, which we expect will result in a financially stronger and more diversified Company,” commented Dr. David Gane, Company CEO. “Having our own suite of imaging software, including XVWEB, a cloud based imaging software service (SaaS) provides LED with an additional stream of high margin revenue, as well as a differentiated product offering and market with which to grow VELscope and imaging device businesses.”

Financial Highlights

LED Medical reported revenue of $2.098 million, which is a decrease of 2% from the three months ended March 31, 2016, and a 13% increase in revenues from the three months ended December 31, 2016.

The net loss was $1.08 million for the three months ended March 31, 2017, as compared to a net loss of $2.05 million for the three months ended March 31, 2016. Inclusive of accounting adjustments, the Company’s calculated gross margin was 49% for the three months ended March 31, 2017, as compared to 25% in the three months ended March 31, 2016.

Total operating expenses for the three months ended March 31, 2017 were $1.79 million, as compared to $2.53 million for the three months ended March 31, 2016. Core operating expenses (excluding stock-based compensation, deferred share unit compensation and other operating expenses) for the three months ended March 31, 2017 were $1.7 million, as compared to $2.2 million for the three months ended March 31, 2016.

The Company had cash of $2.9 million as of March 31, 2017. Cash flow used in operations was $1.39 million during the three months ended March 31, 2017, compared to $684,000 during the three months ended March 31, 2016. The cash outflows from investing activities during the three months ended March 31, 2017 were $10.23 million relating to the purchase of Apteryx, Inc. There were inflows from financing activities for the three months ended March 31, 2017 of $13.6 million attributed to the financing related to the purchase of Apteryx.

Business Highlights, Financial Statements and Management’s Discussion & Analysis

On February 10, 2017, the Company acquired 100% of the common shares of Apteryx, Inc. (“Apteryx”) for aggregate consideration of US $10.25 million. Apteryx is a custom software development company located in Akron, Ohio specializing in medical and dental image processing, data encryption and security, database, data conversion and distributed systems.

The Company closed a series of financings related to the acquisition for gross proceeds of approximately $14.4 million CDN. The Company completed a private placement of 220,711,540 equity units of the Company (the “Equity Units”) for gross proceeds of approximately C$13.3 million. The Equity Units were priced at C$0.06 per Equity Unit, each consisting of one common share and one-half of one common share purchase warrant, with each whole warrant being exercisable for a period of 24 months into one common share of LED at a price of C$0.10 per common share.

The Company also issued senior secured debentures with a principal amount of $1,150,000 CDN maturing 24 months from the closing date. The debenture is attached with a 12% coupon and 2,443,750 common shares of the Company.

Please see the audited consolidated financial statements and related Management’s Discussion & Analysis (“MD&A”) for more details. The interim consolidated financial statements for the three months ended March 31, 2017 and related MD&A have been reviewed and approved by the Company’s Audit Committee and Board of Directors. The Company has prepared this truncated news release to alert investors to its results and that a more detailed explanation and analysis is readily available in the MD&A. These reports have been filed on SEDAR at www.sedar.com and also posted to www.ledmd.com.

Non-IFRS Measures

The following and preceding discussion of financial results includes references to Gross Margin and Core Operating Expenses, which are non-IFRS financial measures. The measure of gross margin is provided as management believes this is a good indicator in evaluating the operating performance of the Company. EBITDA is defined as net loss and comprehensive loss and excludes interest; income taxes; depreciation; amortization; finder’s warrants issuance costs; stock-based compensation; deferred share unit compensation; mark to market adjustments on Canadian dollar denominated warrants; foreign exchange gain or loss; and other income. The measure of working capital is provided as management believes this is a good indicator of the operating liquidity available to the Company.

About LED Medical Diagnostics Inc.

Founded in 2003 and headquartered in Vancouver, British Columbia, Canada, LED Medical Diagnostics Inc., through its wholly-owned subsidiaries LED Dental Inc. and LED Dental Ltd., provide dentists and oral health specialists with advanced diagnostic imaging products and software, in addition to the award-winning VELscope® Vx tissue fluorescence visualization technology. Backed by an experienced leadership team and dedicated to a higher level of service and support, LED Dental is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio.

The Company is currently listed on the TSX Venture Exchange (TSX-V) under the symbol “LMD,” the OTCQB under the symbol “LEDIF,” as well as the Frankfurt Stock Exchange under the symbol “LME.” For more information, call 844.952.7327 or visit www.leddental.com/investor-relations.

Investor Relations:

Bristol Capital
Glen Akselrod
Phone: 905-326-1888 x10
Email: glen@bristolir.com

Media Contact:

LED Dental
Chris Koch
Phone: 678.293.9413
Email: chris.koch@leddental.com

Corporate Contact:

LED Medical
David Gane, CEO
Phone: 604-434-4614 x227
Email: david.gane@leddental.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to the Company’s future growth strategy, its distribution strategy and product offerings, potential expansion of the Company’s technology to other medical applications or markets, or the potential introduction of new technologies by the Company. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation’s actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation’s reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2016. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

1EBITDA or Earnings before Interest, Taxes Depreciation and Amortization is a non-IFRS measure that does not have a standardized meaning and may not be comparable to a similar measure disclosed by other issuers. This measure does not have a comparable GAAP measure. EBITDA referenced here relates to net loss and comprehensive loss and excludes interest, income taxes, depreciation, amortization, finder”s warrants issuance costs, stock-based compensation, deferred share unit compensation, mark to market adjustments on Canadian dollar denominated warrants, foreign exchange gain or loss and other income. This measure does not have a comparable IFRS measure and is used by the Company to manage and evaluate the cash operating loss of the business.

2Gross margin is a non-IFRS measure that does not have a standard meaning and may not be comparable to a similar measure disclosed by other issuers. Gross margin referenced here relates to revenues less cost of sales. This measure does not have a comparable IFRS measure and is used by the Company to manage and evaluate the operating performance of the Company.

3Core operating expense is a non-IFRS measure that does not have a standardized meaning and may not be comparable to a similar measure disclosed by other issuers. This measure does not have a comparable IFRS measure. Core operating expense includes sales and marketing, research and development and administration expense. The Company believes that the inclusion of this no-IFRS measure financial measure provides investors with an alternative presentation useful to investors’ understanding of the Company”s core operating results and trends.

SOURCE: LED Medical Diagnostics Inc.

ReleaseID: 464493

IRVINE, CA / ACCESSWIRE / May 30, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Alliance MMA, Inc. (“Alliance MMA” or the “Company”) (NASDAQ: AMMA). Investors, who purchased or otherwise acquired shares pursuant and/or traceable to the Company’s initial public offering (“IPO”) on or about October 6, 2016, are encouraged to contact the Firm in advance of the June 16, 2017 lead plaintiff motion deadline.

If you purchased Alliance MMA shares on or about the IPO date, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The Complaint alleges that during the Class Period, Alliance MMA made false and/or misleading statements and/or failed to disclose: that the condensed consolidated financial statements for the three months ended June 30, 2016 could not be relied upon due to an error in recognizing as compensation transfers of common stock by an affiliate of the Company to individuals who were, at the time of transfer, or subsequently became, officers, directors, or consultants of Alliance MMA; that the condensed consolidated financial statements for the six months ended June 30, 2016 could not be relied upon because of an error in recognizing as compensation transfers of common stock by an affiliate of Alliance MMA to individuals who were, at the time of transfer, or subsequently became, officers, directors, or consultants of Alliance MMA; and that as a result of the above, Alliance MMA’s statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When this news was announced, Alliance MMA’s stock price lowered materially, which harmed investors according to the Complaint.

If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 464467

LOS ANGELES, CA / ACCESSWIRE / May 30, 2017 / The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, today announced that it will be presenting at the 7th Annual LD Micro Invitational conference on Wednesday, June 7, 2017, at 11:00 a.m. PST / 2 p.m. EST. Peter D. Holt, President and Chief Executive Officer, and John P. Meloun, Chief Financial Officer, will also be available for one-on-one meetings held throughout the day on June 7.

“We look forward to participating in this important investor event,” said Holt. “It’s exciting to have the opportunity to share with potential investors how we are revolutionizing the way in which chiropractic care is being accessed, as we build a retail chain of The Joint brand clinics across the country.”

To schedule a one-on-one meeting with The Joint Corp. during this conference, please contact Wade Hickok at wade@ldmicro.com or the Company’s investor relations representative at peter.vozzo@westwicke.com or (443) 213-0505.

A live webcast and subsequent replay of the presentation can be accessed by visiting the investor relations section of the Company’s website at ir.thejoint.com.

“This year, not only do we have a record number of companies making their LD Micro debuts, but a record number of companies presenting for the first time in their company’s history,” stated Chris Lahiji, President of LD Micro. “LD has established itself as the one venue that brings the most influential players from all segments of the market under one roof.”

The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 180 companies in the small / micro-cap space.

View The Joint Corp.’s profile here: https://www.ldmicro.com/profile/JYNT

Profiles powered by LD Micro – News Compliments of ACCESSWIRE.

About The Joint Corp. (NASDAQ: JYNT)

Based in Scottsdale, Arizona, The Joint is an emerging growth company that is reinventing chiropractic by making quality care convenient and affordable for patients seeking pain relief and ongoing wellness. Its no-appointment policy and convenient hours and locations make care more accessible, and affordable membership plans and packages eliminate the need for insurance. With 370+ clinics nationwide and more than 4 million patient visits annually, The Joint is a key leader in the chiropractic profession. For more information, visit www.thejoint.com or follow the brand on Twitter, Facebook, YouTube and LinkedIn.

Business Structure

The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, Florida, Illinois, Kansas, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Tennessee, and Washington, The Joint and its franchisees provide management services to affiliated professional chiropractic

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Investor Contact:
Peter Vozzo
peter.vozzo@westwicke.com
(443) 213-0505

Media Contact:
The Joint Corp.
Inna Lazarev
inna.lazarev@thejoint.com
(480) 245-5960 x 202

SOURCE: The Joint Corp.

ReleaseID: 464485

IRVINE, CA / ACCESSWIRE / May 30, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT: IMUC). Investors, who purchased or otherwise acquired shares between May 1, 2012 and December 11, 2013, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the June 30, 2017 lead plaintiff motion deadline.

If you purchased ImmunoCellular shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well

The Complaint alleges that during the Class Period, ImmunoCellular issued materially false and/or misleading statements and/or failed to disclose: that the Company retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; and that the market was led to believe that the Company’s clinical studies for its product candidate, ICT-107, were going well, and thus the share price was artificially inflated. When this news was announced, ImmunoCellular’s stock price fell significantly, which harmed investors according to the Complaint. On April 10, 2017, the SEC announced enforcement actions against numerous individuals and entities, including ImmunoCellular, that engaged in stock promotion schemes.

If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 464484

IRVINE, CA / ACCESSWIRE / May 30, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Signet Jewelers Limited (“Signet” or the “Company”) (NYSE: SIG). Investors, who purchased or otherwise acquired the Company’s shares between August 29, 2013 and February 27, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the new, updated July 5, 2017 lead plaintiff motion deadline.

If you purchased shares of Signet during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

The Complaint states that during the Class Period, Signet issued false and misleading statements and/or failed to disclose that alleged sexual harassment by employees of Signet’s Sterling Family of Jewelers division (“Sterling”) – including numerous incidents of sexual assault and rape which were detailed in approximately 249 declarations signed under penalty of perjury by current and former Sterling employees – made it unlikely that the Company would be able to avoid paying a sizable amount of damages in connection with a class action lawsuit filed by Sterling employees. Signet’s stock traded at artificially inflated prices throughout the Class Period as a result of this information being withheld from the market. On February 27, 2017, The Washington Post published a report revealing widespread allegations of sexual harassment made in the private arbitration that implicated Signet’s senior managers and executives. Following the release of this information, Signet’s stock price fell materially, which allegedly caused investors harm.

If you wish to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 464483

IRVINE, CA / ACCESSWIRE / May 30, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Snap Inc. (“Snap” or the “Company”) (NYSE: SNAP). Investors, who purchased or otherwise acquired shares (1) pursuant and/or traceable to Snap’s false and misleading Registration Statement and Prospectus, issued in connection with its initial public offering on or about March 2, 2017 (the “IPO”); and/or (2) on the open market between March 2, 2017 and May 15, 2017, are encouraged to contact the Firm in advance of the July 17, 2017 lead plaintiff motion deadline.

If you purchased Snap shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the Complaint, during the Class Period, Snap made false and/or misleading statements about its reported user growth. On May 10, 2017, post-market, the Company issued its first quarterly report as a public company, disclosing disappointing user growth, being the slowest year-to-year growth rate in at least two years. Following this news, Snap’s stock price dropped materially, which harmed investors according to the Complaint. On May 16, 2017, a report was published stating that former Snap employee, Anthony Pompliano, had filed a lawsuit against Snap, “claim[ing] he was fired after three weeks on the job for raising questions about allegedly false growth metrics [and] seeking whistleblower protection against retaliation by [the] company.”

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 464482

IRVINE, CA / ACCESSWIRE / May 30, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against PCM, Inc. (“PCM” or the “Company”) (NASDAQ: PCMI). Investors, who purchased or otherwise acquired shares between June 17, 2015 and May 2, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the July 3, 2017 lead plaintiff motion deadline.

If you purchased PCM shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

The Complaint alleges that during the Class Period, PCM violated federal securities laws by making materially false and/or misleading statements, and/or failing to disclose material information to investors. In April 2015, PCM acquired En Pointe Technologies, Inc. and publicly filed its supposed financial statements. On May 2, 2017, Seeking Alpha disclosed that PCM alleged that En Pointe’s net income was overstated due to several accounting shenanigans and thus its public statements were materially false and misleading at all relevant times. When this information was announced, the stock price of PCM fell materially, which harmed investors according to the Complaint.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone at (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may be considered Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 464481

IRVINE, CA / ACCESSWIRE / May 30, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against KBR, Inc. (“KBR” or the “Company”) (NYSE: KBR). Investors, who purchased or otherwise acquired shares between February 26, 2016 and April 27, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the July 3, 2017 lead plaintiff motion deadline.

If you purchased KBR shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.

The Complaint alleges that during the Class Period, KBR made false and/or misleading statements and/or failed to disclose that the Company’s United Kingdom subsidiaries violated applicable bribery and corruption laws. On April 28, 2017, the United Kingdom’s Serious Fraud Office confirmed that it had opened an investigation into the activities of KBR’s United Kingdom subsidiaries for suspected offences of bribery and corruption. When this news reached the public, KBR’s stock price dropped materially, which caused investors harms according to the Complaint.

If you wish to learn more about this lawsuit, or if you have questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 464480

LOS ANGELES, CA / ACCESSWIRE / May 30, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against United States Steel Corporation (“U.S. Steel” or the “Company”) (NYSE: X) for possible violations of federal securities laws between November 1, 2016 and April 25, 2017, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the firm prior to the July
3, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, during the Class Period, U.S. Steel issued materially false and/or misleading statements and/or failed to disclose: that while the Company was implementing its Carnegie Way program, it focused on cutting costs and not making investments necessary to position U.S. Steel so that it could respond to improved market conditions; that the Company’s failure to invest in improving capital assets during the industry downturn, in order to report apparent financial improvements, meant that U.S. Steel had higher production costs than its competitors, even in the face of improved pricing, which would negatively impact its financial results; and that U.S. Steel was forestalling expensive capital equipment upgrades in order to boost its short-term financial results at the expense of long-term financial performance, leaving U.S. Steel in need of accelerated, costly equipment upgrades that would leave the Company years away from generating improved financial performance. Following this news, U.S. Steel’s stock price declined materially, which caused investors harm according to the Complaint.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethics rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 464479